DCGI Approves ENTOD’s Eye Drops for Presbyopia

The Drugs Controller General of India (DCGI) has approved ENTOD Pharmaceuticals' PresVu eye drops, designed to reduce the need for reading glasses in individuals with presbyopia, a common age-related vision issue.

ENTOD Pharmaceuticals’ PresVu eye drops have been developed specifically to address presbyopia, a condition affecting individuals over 40 by reducing their dependency on reading glasses.
The approval from DCGI follows a recommendation from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
PresVu eye drops employ advanced dynamic buffer technology that quickly adjusts to tear pH, ensuring consistent efficacy and safety over prolonged use.
The eye drops also offer the additional benefit of lubricating the eyes, enhancing comfort for users who might use them regularly for years.
ENTOD Pharmaceuticals has applied for a patent for the formulation and process of PresVu, underscoring its innovative approach to treating presbyopia.